Article
Reactivation of ERK and Akt confers resistance of mutant BRAF colon cancer cells to the HSP90 inhibitor AUY922.
Oncotarget - 2 Aug 2016
Wang Chun Yan, Guo Su Tang, Wang Jia Yu, Yan Xu Guang, Farrelly Margaret, Zhang Yuan Yuan, Liu Fen, Yari Hamed, La Ting, Lei Fu Xi, Jin Lei, Zhang Xu Dong, Jiang Chen Chen
Abstract excerpt
Oncogenic mutations of BRAF occur in approximately 10% of colon cancers and are associated with their resistance to clinically available therapeutic drugs and poor prognosis of the patients. Here we report that colon cancer cells with mutant BRAF are also resistant to the heat shock protein 90 (HSP90) inhibitor AUY922, and that this is caused by rebound activation of ERK and Akt. Although AUY922 triggered rapid...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.